Lawrence Young, MD

• Adam V Wisnewski
• Albert Ko
• Albert Sinusas
• Ana Luisa Perdigoto
• Andrew Wang
• Caihong Qiu
• Catherine Viscoli
• Daniel Jacoby
• Daniela Tirziu
• Deborah Proctor
• Dhanpat Jain
• Diane Krause
• Edward J Miller
• Erica Herzog
• Fadi Gabriel Akar
• Forrester Lee
• Frans Wackers
• Fred Sanford Gorelick
• Gary Désir
• Gerald I Shulman
• Guadalupe Garcia-Tsao
• Hai Feng Zhang
• Hamid Mojibian
• James Revkin
• Jeffrey Pollak
• Jeffrey Testani
• Jennefer Par-Young
• Jenny Huanjiao Zhou
• Jeptha Curtis
• Jian Liu
• Jianlei Gu
• Jianying Dong
• Jiasheng Zhang
• Joseph Akar
• Joseph Schindler
• Junghee Jenny Shin
• Karl Insogna
• Katharine Henderson
• Kristin Stendahl
• Lauren A. Baldassarre
• Lawrence Staib
• Lin Wang
• Maor Sauler
• Mario Kahn
• Michael Caplan
• Michael Cleman
• Muhammad Riaz
• Nabil Boutagy
• Raimund Herzog
• Richard Bucala
• Robert I. White
• Robert Safirstein
• Robert Soufer
• Rohan Khera
• Sang-Hun Kim
• Silvio Inzucchi
• Stephanie Thorn
• Steven Pfau
• Stuart Campbell
• Veena Rao
• Wade Schulz
• Walter Kernan
• William Chang
• Xiaojia (Sasha) Guo
• Xuefei Tian
• Yibing Qyang
• Zhenwu Zhuang

Cell Survival; Diabetes Mellitus; Insulin Resistance; Myocardial Ischemia; Apoptosis; Glucose Transporter Type 4; AMP-Activated Protein Kinases

• A pref-1-controlled non-inflammatory mechanism of insulin resistanceHuang Y, Cui D, Chen L, Tong H, Wu H, Muller G, Qi Y, Wang S, Xu J, Gao X, Fifield K, Wang L, Xia Z, Vanderluit J, Liu S, Leng L, Sun G, McGuire J, Young L, Bucala R, Qi D. A pref-1-controlled non-inflammatory mechanism of insulin resistance. IScience 2023, 26: 106923. PMCID: PMC10239698, DOI: 10.1016/j.isci.2023.106923.
• A pref-1-controlled non-inflammatory mechanism of insulin resistanceHuang Y, Cui D, Chen L, Tong H, Wu H, Muller G, Qi Y, Wang S, Xu J, Gao X, Fifield K, Wang L, Xia Z, Vanderluit J, Liu S, Leng L, Sun G, McGuire J, Young L, Bucala R, Qi D. A pref-1-controlled non-inflammatory mechanism of insulin resistance. IScience 2023, 26: 106923. PMID: 37283810, PMCID: PMC10239698, DOI: 10.1016/j.isci.2023.106923.
• Abstract 13764: Renalase Peptide Agonist Therapy Normalizes the Cardiac Response to Pressure Overload in Chronic Kidney DiseaseNair G, Zhang J, Guo X, guerrera N, Wu X, Hu X, Gorelick F, Safirstein R, Giordano F, Young L, Desir G. Abstract 13764: Renalase Peptide Agonist Therapy Normalizes the Cardiac Response to Pressure Overload in Chronic Kidney Disease. Circulation 2022, 146: a13764-a13764. DOI: 10.1161/circ.146.suppl_1.13764.
• Abstract 13661: An Adaptive Strategy of Predictive Enrichment to Increase Efficiency of Randomized Clinical Trials Using Machine Learning: A Simulation of the IRIS TrialOikonomou E, Suchard M, Kernan W, Young L, Inzucchi S, Khera R. Abstract 13661: An Adaptive Strategy of Predictive Enrichment to Increase Efficiency of Randomized Clinical Trials Using Machine Learning: A Simulation of the IRIS Trial. Circulation 2022, 146: a13661-a13661. DOI: 10.1161/circ.146.suppl_1.13661.
• MIF is a Common Genetic Determinant of COVID-19 Symptomatic Infection and SeverityShin JJ, Fan W, Par-Young J, Piecychna M, Leng L, Israni-Winger K, Qing H, Gu J, Zhao H, Schulz WL, Unlu S, Kuster J, Young G, Liu J, Ko AI, Garcia A, Sauler M, Wisnewski AV, Young L, Orduña A, Wang A, Klementina O, Garcia AB, Hegyi P, Armstrong ME, Mitchell P, Ordiz DB, Garami A, Kang I, Bucala R. MIF is a Common Genetic Determinant of COVID-19 Symptomatic Infection and Severity. QJM 2022, 116: hcac234. PMID: 36222594, PMCID: PMC9620729, DOI: 10.1093/qjmed/hcac234.
• Abstract P1098: Atrial Deletion Of AMPK Promotes Atrial Oxidative Stress And The Formation Of Delayed Afterdepolarizations Within The Inter-atrial Pulmonary Vein JunctionCacheux M, Ma Y, Wu X, Akar J, Young L, Akar F. Abstract P1098: Atrial Deletion Of AMPK Promotes Atrial Oxidative Stress And The Formation Of Delayed Afterdepolarizations Within The Inter-atrial Pulmonary Vein Junction. Circulation Research 2022, 131: ap1098-ap1098. DOI: 10.1161/res.131.suppl_1.p1098.
• Abstract P3052: Dysregulation Of The Ampk-drp1 Axis Promotes Pathophysiological Remodeling Of Mitochondrial Ultrastructure And Ventricular Electrophysiological FunctionRudokas M, Cacheux M, Wu X, Young L, Akar F. Abstract P3052: Dysregulation Of The Ampk-drp1 Axis Promotes Pathophysiological Remodeling Of Mitochondrial Ultrastructure And Ventricular Electrophysiological Function. Circulation Research 2022, 131: ap3052-ap3052. DOI: 10.1161/res.131.suppl_1.p3052.
• Central vs site outcome adjudication in the IRIS trialForman R, Viscoli CM, Bath PM, Furie KL, Guarino P, Inzucchi SE, Young L, Kernan WN. Central vs site outcome adjudication in the IRIS trial. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106667. PMID: 35901589, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106667.
• 122-LB: Effect of Dapagliflozin on Mitochondrial Metabolism and Cardiac Function in the Failing HeartGOEDEKE L, MA Y, ZHANG J, GUERRERA N, WU X, ZHANG D, KAHN M, ZHANG X, YOUNG L, SHULMAN G. 122-LB: Effect of Dapagliflozin on Mitochondrial Metabolism and Cardiac Function in the Failing Heart. Diabetes 2022, 71 DOI: 10.2337/db22-122-lb.
• Atrial AMP-activated protein kinase is critical for prevention of dysregulation of electrical excitability and atrial fibrillationSu KN, Ma Y, Cacheux M, Ilkan Z, Raad N, Muller GK, Wu X, Guerrera N, Thorn SL, Sinusas AJ, Foretz M, Viollet B, Akar JG, Akar FG, Young LH. Atrial AMP-activated protein kinase is critical for prevention of dysregulation of electrical excitability and atrial fibrillation. JCI Insight 2022, 7: e141213. PMID: 35451373, PMCID: PMC9089788, DOI: 10.1172/jci.insight.141213.
• Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic CardiomyopathyRiaz M, Park J, Sewanan LR, Ren Y, Schwan J, Das SK, Pomianowski PT, Huang Y, Ellis MW, Luo J, Liu J, Song L, Chen IP, Qiu C, Yazawa M, Tellides G, Hwa J, Young LH, Yang L, Marboe CC, Jacoby DL, Campbell SG, Qyang Y. Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy. Circulation 2022, 145: 1238-1253. PMID: 35384713, PMCID: PMC9109819, DOI: 10.1161/circulationaha.121.056265.
• Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistanceSpence JD, Viscoli C, Kernan WN, Young LH, Furie K, DeFronzo R, Abdul‐Ghani M, Dandona P, Inzucchi SE. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes Obesity And Metabolism 2022, 24: 1150-1158. PMID: 35253334, DOI: 10.1111/dom.14687.
• Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung InfectionSharma L, Peng X, Qing H, Hilliard BK, Kim J, Swaminathan A, Tian J, Israni-Winger K, Zhang C, Habet V, Wang L, Gupta G, Tian X, Ma Y, Shin HJ, Kim SH, Kang MJ, Ishibe S, Young LH, Kotenko S, Compton S, Wilen CB, Wang A, Dela Cruz CS. Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung Infection. Journal Of Virology 2021, 96: e01241-21. PMID: 34705554, PMCID: PMC8791255, DOI: 10.1128/jvi.01241-21.
• 323-OR: SGLT2 Inhibition Promotes Myocardial Ketone Utilization in the Normal and Failing HeartGOEDEKE L, LEE J, MA Y, HU X, ZHANG J, DONG J, GALSGAARD K, GUERRERA N, HAEDERSDAL S, ZHANG X, PERRY R, CLINE G, YOUNG L, SHULMAN G. 323-OR: SGLT2 Inhibition Promotes Myocardial Ketone Utilization in the Normal and Failing Heart. Diabetes 2021, 70 DOI: 10.2337/db21-323-or.
• NAD Repletion TherapyAkar FG, Young LH. NAD Repletion Therapy. Circulation Research 2021, 128: 1642-1645. PMID: 34043421, PMCID: PMC8513806, DOI: 10.1161/circresaha.121.319308.
• Right Ventricular Fatty Infiltration With an Abnormal ECGOdanovic N, Mojibian HR, Young LH. Right Ventricular Fatty Infiltration With an Abnormal ECG. JACC Case Reports 2021, 3: 314-318. PMID: 34317526, PMCID: PMC8310990, DOI: 10.1016/j.jaccas.2020.11.017.
• Abstract 14834: Protective Role of Cardiomyocyte-derived Ddt in Ischemic CardiomyopathyMa Y, Hu X, Pfau D, Wu X, Rao V, Testani J, Margulies K, Bucala R, Young L. Abstract 14834: Protective Role of Cardiomyocyte-derived Ddt in Ischemic Cardiomyopathy. Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.14834.
• Abstract 14844: Ampk is Required for Maintaining Atrial Metabolism and Oxidative StressMa Y, Wu X, Hu X, Cline G, Akar F, Young L. Abstract 14844: Ampk is Required for Maintaining Atrial Metabolism and Oxidative Stress. Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.14844.
• Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular MalformationsKim AS, Henderson KJ, Pawar S, Kim MJ, Punjani S, Pollak JS, Fahey JT, Garcia‐Tsao G, Sugeng L, Young LH. Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular Malformations. Journal Of The American Heart Association 2020, 9: e016197. PMID: 33054561, PMCID: PMC7763373, DOI: 10.1161/jaha.120.016197.
• Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndromeYang B, Huang Y, Zhang H, Huang Y, Zhou HJ, Young L, Xiao H, Min W. Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome. Journal Of Molecular And Cellular Cardiology 2019, 138: 291-303. PMID: 31751569, DOI: 10.1016/j.yjmcc.2019.10.009.
• Diabetes prevention and cardiovascular complicationsInzucchi SE, Viscoli CM, Young LH, Kernan WN. Diabetes prevention and cardiovascular complications. Diabetologia 2019, 62: 2161-2162. PMID: 31522231, DOI: 10.1007/s00125-019-04999-3.
• Cardiomyocyte d-dopachrome tautomerase protects against heart failureMa Y, Su KN, Pfau D, Rao VS, Wu X, Hu X, Leng L, Du X, Piecychna M, Bedi K, Campbell SG, Eichmann A, Testani JM, Margulies KB, Bucala R, Young LH. Cardiomyocyte d-dopachrome tautomerase protects against heart failure. JCI Insight 2019, 4: e128900. PMID: 31484822, PMCID: PMC6777911, DOI: 10.1172/jci.insight.128900.
• GDF15 Is an Inflammation-Induced Central Mediator of Tissue ToleranceLuan HH, Wang A, Hilliard B, Carvalho F, Rosen CE, Ahasic A, Herzog E, Kang I, Pisani MA, Yu S, Zhang C, Ring A, Young L, Medzhitov R. GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance. Cell 2019, 178: 1231-1244.e11. PMID: 31402172, PMCID: PMC6863354, DOI: 10.1016/j.cell.2019.07.033.
• Abstract 875: Cardiomyocyte Derived DDT Protects Against Myocardial Infarction Induced Heart FailureMa Y, Hu X, Wu X, Pfau D, Leng L, Bedi K, Margulies K, Bucala R, Young L. Abstract 875: Cardiomyocyte Derived DDT Protects Against Myocardial Infarction Induced Heart Failure. Circulation Research 2019, 125 DOI: 10.1161/res.125.suppl_1.875.
• Presentation of Liver Failure From a Pericardial MassNguyen VQ, Workman V, Stendahl K, Young L, Sklar J, Baldassarre LA. Presentation of Liver Failure From a Pericardial Mass. Circulation Cardiovascular Imaging 2019, 12: e008672. PMID: 31167559, DOI: 10.1161/circimaging.118.008672.
• Pioglitazone Therapy in Patients With Stroke and PrediabetesSpence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, Furie KL, Lovejoy AM, Young LH, Kernan WN. Pioglitazone Therapy in Patients With Stroke and Prediabetes. JAMA Neurology 2019, 76: 526-535. PMID: 30734043, PMCID: PMC6515584, DOI: 10.1001/jamaneurol.2019.0079.
• Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart FailurePfau D, Thorn SL, Zhang J, Mikush N, Renaud JM, Klein R, deKemp RA, Wu X, Hu X, Sinusas AJ, Young LH, Tirziu D. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure. Scientific Reports 2019, 9: 5791. PMID: 30962467, PMCID: PMC6453892, DOI: 10.1038/s41598-019-42113-0.
• Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and ObesityDearborn JL, Viscoli CM, Young LH, Gorman MJ, Furie KL, Kernan WN. Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. Stroke 2019, 50: 713-717. PMID: 30786849, PMCID: PMC6391736, DOI: 10.1161/strokeaha.118.024008.
• Abstract TMP92: Pioglitazone for Secondary Stroke Prevention in Pre-diabetes: Implications for Real-world PracticeSpence J, Viscoli C, Dearborn-Tomazos J, Furie K, Ford G, Young L, Inzucchi S, Gorman M, Lovejoy A, Kernan W. Abstract TMP92: Pioglitazone for Secondary Stroke Prevention in Pre-diabetes: Implications for Real-world Practice. Stroke 2019, 50 DOI: 10.1161/str.50.suppl_1.tmp92.
• Abstract WP525: Adherence and Adherence Recovery in a Stroke TrialKernan W, Viscoli C, Young L, Gorman M. Abstract WP525: Adherence and Adherence Recovery in a Stroke Trial. Stroke 2019, 50 DOI: 10.1161/str.50.suppl_1.wp525.
• Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture RiskViscoli CM, Kent DM, Conwit R, Dearborn JL, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH, Kernan WN, Investigators F. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke 2018, 50: 95-100. PMID: 30580725, PMCID: PMC6557695, DOI: 10.1161/strokeaha.118.022745.
• Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular diseaseDearborn JL, Viscoli CM, Inzucchi SE, Young LH, Kernan WN. Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease. International Journal Of Stroke 2018, 14: 639-645. PMID: 30507360, DOI: 10.1177/1747493018816425.
• Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapyCui D, Peng Y, Zhang C, Li Z, Su Y, Qi Y, Xing M, Li J, Kim GE, Su KN, Xu J, Wang M, Ding W, Piecychna M, Leng L, Hirasawa M, Jiang K, Young L, Xu Y, Qi D, Bucala R. Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy. Journal Of Clinical Investigation 2018, 128: 4997-5007. PMID: 30295645, PMCID: PMC6205380, DOI: 10.1172/jci93090.
• Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With PioglitazoneYoung LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.
• What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial?INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.
• Evolution of Intrahepatic Shunts in a Patient With Hereditary Hemorrhagic Telangiectasia.Haghighat L, Brandt EJ, Proctor DD, Garcia-Tsao G, Pollak J, Young L. Evolution of Intrahepatic Shunts in a Patient With Hereditary Hemorrhagic Telangiectasia. Annals Of Internal Medicine 2018, 169: 508-509. PMID: 29868721, DOI: 10.7326/l18-0036.
• In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in RodentsBoutagy NE, Wu J, Cai Z, Zhang W, Booth CJ, Kyriakides TC, Pfau D, Mulnix T, Liu Z, Miller EJ, Young LH, Carson RE, Huang Y, Liu C, Sinusas AJ. In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents. JACC Basic To Translational Science 2018, 3: 378-390. PMID: 30062224, PMCID: PMC6058999, DOI: 10.1016/j.jacbts.2018.02.003.
• Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylationWang D, Hu X, Lee SH, Chen F, Jiang K, Tu Z, Liu Z, Du J, Wang L, Yin C, Liao Y, Shang H, Martin KA, Herzog RI, Young LH, Qian L, Hwa J, Xiang Y. Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation. JACC Basic To Translational Science 2018, 3: 350-362. PMID: 30062222, PMCID: PMC6058960, DOI: 10.1016/j.jacbts.2018.01.005.
• ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR THERAPY PROMOTES EARLY ANGIOGENESIS AND IMPROVES MYOCARDIAL PERFUSION INHIBITING POST-INFARCT REMODELINGThorn S, Tirziu D, Pfau D, Mikush N, Zhang J, Renaud J, Klein R, deKemp R, Wu X, Hu X, Young L, Sinusas A. ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR THERAPY PROMOTES EARLY ANGIOGENESIS AND IMPROVES MYOCARDIAL PERFUSION INHIBITING POST-INFARCT REMODELING. Journal Of The American College Of Cardiology 2018, 71: a1466. DOI: 10.1016/s0735-1097(18)32007-2.
• THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIABrandt E, Haghighat L, Garcia-Tsao G, Henderson K, Pollak J, Proctor D, Young L. THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA. Journal Of The American College Of Cardiology 2018, 71: a2393. DOI: 10.1016/s0735-1097(18)32934-6.
• Abstract 101: Pioglitazone Prevents Stroke in Patients With a Recent TIA or Ischemic Stroke: a Secondary Analysis of the IRIS TrialYaghi S, Furie K, Viscoli C, Kamel H, Gorman M, Dearborn J, Young L, Inzucchi S, Lovejoy A, Kasner S, Conwit R, Kernan W. Abstract 101: Pioglitazone Prevents Stroke in Patients With a Recent TIA or Ischemic Stroke: a Secondary Analysis of the IRIS Trial. Stroke 2018, 49 DOI: 10.1161/str.49.suppl_1.101.
• AMP-activated protein kinase and adenosine are both metabolic modulators that regulate chloride secretion in the shark rectal gland (Squalus acanthias)Neuman RI, van Kalmthout JAM, Pfau DJ, Menendez DM, Young LH, Forrest JN. AMP-activated protein kinase and adenosine are both metabolic modulators that regulate chloride secretion in the shark rectal gland (Squalus acanthias). American Journal Of Physiology - Cell Physiology 2017, 314: c473-c482. PMID: 29351415, PMCID: PMC5966785, DOI: 10.1152/ajpcell.00171.2017.
• Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial InfarctionKernan WN, Viscoli CM, Dearborn JL, Kent DM, Conwit R, Fayad P, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurology 2017, 74: 1319-1327. PMID: 28975241, PMCID: PMC5710663, DOI: 10.1001/jamaneurol.2017.2136.
• Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic StrokeYaghi S, Furie KL, Viscoli CM, Kamel H, Gorman M, Dearborn J, Young LH, Inzucchi SE, Lovejoy AM, Kasner SE, Conwit R, Kernan WN. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke. Circulation 2017, 137: 455-463. PMID: 29084736, DOI: 10.1161/circulationaha.117.030458.
• Response by Young et al to Letters Regarding Article, “Cardiac Outcomes After Ischemic Stroke or Transient Ischemic AttackYoung LH, Viscoli CM, Inzucchi SE, Kernan WN. Response by Young et al to Letters Regarding Article, “Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation 2017, 136: 1567-1568. PMID: 29038213, PMCID: PMC5683402, DOI: 10.1161/circulationaha.117.030513.
• Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trialFurie KL, Viscoli CM, Gorman M, Ford GA, Young LH, Inzucchi SE, Guarino PD, Lovejoy AM, Conwit R, Tanne D, Kernan WN. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. Journal Of Neurology Neurosurgery & Psychiatry 2017, 89: 21. PMID: 28939682, DOI: 10.1136/jnnp-2017-316361.
• Smoking cessation and outcome after ischemic stroke or TIAEpstein KA, Viscoli CM, Spence JD, Young LH, Inzucchi SE, Gorman M, Gerstenhaber B, Guarino PD, Dixit A, Furie KL, Kernan WN. Smoking cessation and outcome after ischemic stroke or TIA. Neurology 2017, 89: 1723-1729. PMID: 28887378, PMCID: PMC5644463, DOI: 10.1212/wnl.0000000000004524.
• MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeuticsTilstam PV, Qi D, Leng L, Young L, Bucala R. MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics. Expert Opinion On Therapeutic Targets 2017, 21: 671-683. PMID: 28562118, PMCID: PMC6130320, DOI: 10.1080/14728222.2017.1336227.
• Pioglitazone and cardiovascular risk reductionPerdigoto AL, Young LH, Inzucchi SE. Pioglitazone and cardiovascular risk reduction. Cardiovascular Endocrinology & Metabolism 2017, 6: 55-61. PMID: 31646121, PMCID: PMC6768516, DOI: 10.1097/xce.0000000000000110.
• Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous MalformationsChizinga M, Rudkovskaia AA, Henderson K, Pollak J, Garcia-Tsao G, Young LH, Fares WH. Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations. American Journal Of Respiratory And Critical Care Medicine 2017, 196: 1353-1356. PMID: 28375020, DOI: 10.1164/rccm.201702-0267le.
• Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN. Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692. Diabetes Care 2017, 40: e47-e48. PMID: 28325804, PMCID: PMC5360290, DOI: 10.2337/dci16-0048.
• Cardiac Outcomes After Ischemic Stroke or Transient Ischemic AttackYoung LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation 2017, 135: 1882-1893. PMID: 28246237, PMCID: PMC5511545, DOI: 10.1161/circulationaha.116.024863.
• Abstract 74: Obesity and the Risk of Recurrent Vascular Events in Patients with Ischemic Stroke: Insights from the Insulin Resistance Intervention after Stroke (IRIS) TrialDearborn J, Viscoli C, Inzucchi S, Young L, Kernan W. Abstract 74: Obesity and the Risk of Recurrent Vascular Events in Patients with Ischemic Stroke: Insights from the Insulin Resistance Intervention after Stroke (IRIS) Trial. Stroke 2017, 48 DOI: 10.1161/str.48.suppl_1.74.
• Pioglitazone and cardiovascular risk reduction: time for a second look?Pioglitazone and cardiovascular risk reduction: time for a second look? Cardiovascular Endocrinol 2017;6:55-61
• Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. The Journal Of Clinical Endocrinology & Metabolism 2016, 102: 914-922. PMID: 27935736, PMCID: PMC5460686, DOI: 10.1210/jc.2016-3237.
• PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasiaOla R, Dubrac A, Han J, Zhang F, Fang JS, Larrivée B, Lee M, Urarte AA, Kraehling JR, Genet G, Hirschi KK, Sessa WC, Canals FV, Graupera M, Yan M, Young LH, Oh PS, Eichmann A. PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nature Communications 2016, 7: 13650. PMID: 27897192, PMCID: PMC5141347, DOI: 10.1038/ncomms13650.
• Pioglitazone after Ischemic Stroke or Transient Ischemic AttackViscoli CM, Kernan WN, Young LH. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal Of Medicine 2016, 375: 702-704. PMID: 27532845, DOI: 10.1056/nejmc1605904.
• Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016, 39: 1684-92. PMID: 27465265, PMCID: PMC5033078, DOI: 10.2337/dc16-0798.
• ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarctionBartulos O, Zhuang ZW, Huang Y, Mikush N, Suh C, Bregasi A, Wang L, Chang W, Krause DS, Young LH, Pober JS, Qyang Y. ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction. JCI Insight 2016, 1: e80920. PMID: 27525311, PMCID: PMC4982472, DOI: 10.1172/jci.insight.80920.
• miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in HeartLi N, Hwangbo C, Jaba IM, Zhang J, Papangeli I, Han J, Mikush N, Larrivée B, Eichmann A, Chun HJ, Young LH, Tirziu D. miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart. Scientific Reports 2016, 6: 21228. PMID: 26888314, PMCID: PMC4758045, DOI: 10.1038/srep21228.
• Pioglitazone after Ischemic Stroke or Transient Ischemic AttackKernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal Of Medicine 2016, 374: 1321-1331. PMID: 26886418, PMCID: PMC4887756, DOI: 10.1056/nejmoa1506930.
• AMPK is critical for mitochondrial function during reperfusion after myocardial ischemiaZaha VG, Qi D, Su KN, Palmeri M, Lee HY, Hu X, Wu X, Shulman GI, Rabinovitch PS, Russell RR, Young LH. AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia. Journal Of Molecular And Cellular Cardiology 2015, 91: 104-113. PMID: 26746142, PMCID: PMC4839186, DOI: 10.1016/j.yjmcc.2015.12.032.
• LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillationKim GE, Ross JL, Xie C, Su KN, Zaha VG, Wu X, Palmeri M, Ashraf M, Akar JG, Russell KS, Akar FG, Young LH. LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation. Cardiovascular Research 2015, 108: 197-208. PMID: 26378152, PMCID: PMC4571838, DOI: 10.1093/cvr/cvv212.
• AMPK: energy sensor and survival mechanism in the ischemic heartQi D, Young LH. AMPK: energy sensor and survival mechanism in the ischemic heart. Trends In Endocrinology And Metabolism 2015, 26: 422-429. PMID: 26160707, PMCID: PMC4697457, DOI: 10.1016/j.tem.2015.05.010.
• AMPK and the Atrial Response to Metabolic Inhibition∗Kim GE, Young LH. AMPK and the Atrial Response to Metabolic Inhibition∗. Journal Of The American College Of Cardiology 2015, 66: 59-61. PMID: 26139059, DOI: 10.1016/j.jacc.2015.04.054.
• Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD studyChyun DA, Wackers FJ, Inzucchi SE, Jose P, Weiss C, Davey JA, Heller GV, Iskandrian AE, Young LH, Investigators F. Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. SAGE Open Medicine 2015, 3: 2050312114568476. PMID: 26770763, PMCID: PMC4679226, DOI: 10.1177/2050312114568476.
• Abstract 15983: Increased Mitochondrial Reactive Oxygen Species Lead to Deleterious JNK Signaling and Ischemia-Reperfusion Injury in AMPK-Inactivated HeartsZaha V, Qi D, Lee H, Hu X, Wu X, Shulman G, Rabinovitch P, Young L. Abstract 15983: Increased Mitochondrial Reactive Oxygen Species Lead to Deleterious JNK Signaling and Ischemia-Reperfusion Injury in AMPK-Inactivated Hearts. Circulation 2014, 130 DOI: 10.1161/circ.130.suppl_2.15983.
• Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke TrialViscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Lovejoy AM, Parsons MW, Peduzzi PN, Ringleb PA, Schwartz GG, Spence JD, Tanne D, Young LH, Kernan WN, investigators I. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial. American Heart Journal 2014, 168: 823-829.e6. PMID: 25458644, PMCID: PMC4254508, DOI: 10.1016/j.ahj.2014.07.016.
• The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injuryQi D, Atsina K, Qu L, Hu X, Wu X, Xu B, Piecychna M, Leng L, Fingerle-Rowson G, Zhang J, Bucala R, Young LH. The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury. Journal Of Clinical Investigation 2014, 124: 3540-3550. PMID: 24983315, PMCID: PMC4109524, DOI: 10.1172/jci73061.
• LKB1 is a Critical Regulator of Early Atrial Growth and Electrophysiological FunctionKim G, Ross J, Xie C, Wu X, Palmeri M, Zaha V, Ashraf M, Akar J, Russell K, Akar F, Young L. LKB1 is a Critical Regulator of Early Atrial Growth and Electrophysiological Function. Biophysical Journal 2014, 106: 304a. DOI: 10.1016/j.bpj.2013.11.1764.
• Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heartLi J, Qi D, Cheng H, Hu X, Miller EJ, Wu X, Russell KS, Mikush N, Zhang J, Xiao L, Sherwin RS, Young LH. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 16133-16138. PMID: 24043794, PMCID: PMC3791748, DOI: 10.1073/pnas.1312775110.
• Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal TransductionWang J, Tong C, Yan X, Yeung E, Gandavadi S, Hare AA, Du X, Chen Y, Xiong H, Ma C, Leng L, Young LH, Jorgensen WL, Li J, Bucala R. Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal Transduction. Circulation 2013, 128: 225-236. PMID: 23753877, PMCID: PMC3781594, DOI: 10.1161/circulationaha.112.000862.
• Bevacizumab: Finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasiaYoung LH, Henderson KJ, White RI, Garcia‐Tsao G. Bevacizumab: Finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia. Hepatology 2013, 58: 442-445. PMID: 23686865, DOI: 10.1002/hep.26472.
• NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growthJaba IM, Zhuang ZW, Li N, Jiang Y, Martin KA, Sinusas AJ, Papademetris X, Simons M, Sessa WC, Young LH, Tirziu D. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. Journal Of Clinical Investigation 2013, 123: 1718-1731. PMID: 23454748, PMCID: PMC3613910, DOI: 10.1172/jci65112.
• The heart rate response to adenosine: A simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetesHage FG, Wackers FJ, Bansal S, Chyun DA, Young LH, Inzucchi SE, Iskandrian AE. The heart rate response to adenosine: A simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. International Journal Of Cardiology 2012, 167: 2952-2957. PMID: 22981277, PMCID: PMC3723723, DOI: 10.1016/j.ijcard.2012.08.011.
• AMP-Activated Protein Kinase Regulation and Biological Actions in the HeartZaha VG, Young LH. AMP-Activated Protein Kinase Regulation and Biological Actions in the Heart. Circulation Research 2012, 111: 800-814. PMID: 22935535, PMCID: PMC4397099, DOI: 10.1161/circresaha.111.255505.
• Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activationShugrue C, Alexandre M, de Villalvilla A, Kolodecik TR, Young LH, Gorelick FS, Thrower EC. Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation. AJP Gastrointestinal And Liver Physiology 2012, 303: g723-g732. PMID: 22821946, PMCID: PMC3468535, DOI: 10.1152/ajpgi.00082.2012.
• MIF in Cardiovascular DiseaseMiller E, Qi D, Li J, Young L. MIF in Cardiovascular Disease. 2012, 347-358. DOI: 10.1142/9789814335362_0018.
• THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDYHage F, Wackers F, Bansal S, Chyun D, Young L, Inzucchi S, Iskandrian A. THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDY. Journal Of The American College Of Cardiology 2012, 59: e1162. DOI: 10.1016/s0735-1097(12)61163-2.
• Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: Results from the DIAD studyTandon S, Wackers F, Inzucchi SE, Bansal S, Staib LH, Chyun DA, Davey JA, Young LH. Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: Results from the DIAD study. Diabetes And Vascular Disease Research 2012, 9: 124-130. PMID: 22228772, DOI: 10.1177/1479164111431470.
• SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDYTandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F. SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY. Journal Of The American College Of Cardiology 2011, 57: e745. DOI: 10.1016/s0735-1097(11)60745-6.
• A small molecule AMPK activator protects the heart against ischemia–reperfusion injuryKim AS, Miller EJ, Wright TM, Li J, Qi D, Atsina K, Zaha V, Sakamoto K, Young LH. A small molecule AMPK activator protects the heart against ischemia–reperfusion injury. Journal Of Molecular And Cellular Cardiology 2011, 51: 24-32. PMID: 21402077, PMCID: PMC4005884, DOI: 10.1016/j.yjmcc.2011.03.003.
• AMP-activated Protein Kinase (AMPK) Activation and Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Induce Ca2+-independent Deposition of Tight Junction Components at the Plasma Membrane* ♦Zhang L, Jouret F, Rinehart J, Sfakianos J, Mellman I, Lifton RP, Young LH, Caplan MJ. AMP-activated Protein Kinase (AMPK) Activation and Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Induce Ca2+-independent Deposition of Tight Junction Components at the Plasma Membrane* ♦. Journal Of Biological Chemistry 2011, 286: 16879-16890. PMID: 21383016, PMCID: PMC3089531, DOI: 10.1074/jbc.m110.186932.
• Risk stratification in diabetes: Not all patients or perfusion defects are the sameYoung LH. Risk stratification in diabetes: Not all patients or perfusion defects are the same. Journal Of Nuclear Cardiology 2010, 17: 990-992. PMID: 21042899, DOI: 10.1007/s12350-010-9306-3.
• Five-Year Outcomes in High-Risk Participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study A post hoc analysisBansal S, Wackers FJ, Inzucchi SE, Chyun DA, Davey JA, Staib LH, Young LH, . Five-Year Outcomes in High-Risk Participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study A post hoc analysis. Diabetes Care 2010, 34: 204-209. PMID: 20929989, PMCID: PMC3005488, DOI: 10.2337/dc10-1194.
• CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIALBansal S, Wackers F, Inzucchi S, Young L, Chyun D. CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIAL. Journal Of The American College Of Cardiology 2010, 55: a141.e1325. DOI: 10.1016/s0735-1097(10)61326-5.
• Diet-induced obesity obstructs insulin signaling in the heartYoung LH. Diet-induced obesity obstructs insulin signaling in the heart. AJP Heart And Circulatory Physiology 2009, 298: h306-h307. PMID: 19940075, DOI: 10.1152/ajpheart.01088.2009.
• Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusionQi D, Hu X, Wu X, Merk M, Leng L, Bucala R, Young LH. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. Journal Of Clinical Investigation 2009, 119: 3807-3816. PMID: 19920350, PMCID: PMC2786800, DOI: 10.1172/jci39738.
• Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes—ReplyWackers F, Young L. Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes—Reply. JAMA 2009, 302: 735-737. DOI: 10.1001/jama.2009.1190.
• Lessons learned from the detection of ischemia in asymptomatic diabetics (DIAD) studyWackers FJ, Young LH. Lessons learned from the detection of ischemia in asymptomatic diabetics (DIAD) study. Journal Of Nuclear Cardiology 2009, 16: 855. PMID: 19685266, DOI: 10.1007/s12350-009-9138-1.
• A Crystallized View of AMPK ActivationYoung LH. A Crystallized View of AMPK Activation. Cell Metabolism 2009, 10: 5-6. PMID: 19583947, DOI: 10.1016/j.cmet.2009.06.008.
• International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasiaFaughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. Journal Of Medical Genetics 2009, 48: 73. PMID: 19553198, DOI: 10.1136/jmg.2009.069013.
• The pulmonary vascular complications of hereditary haemorrhagic telangiectasia.Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. The European Respiratory Journal 2009, 33: 1186-94. PMID: 19407052, DOI: 10.1183/09031936.00061308.
• Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes : The DIAD Study: A Randomized Controlled TrialYoung LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE, Investigators F. Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes : The DIAD Study: A Randomized Controlled Trial. JAMA 2009, 301: 1547-1555. PMID: 19366774, PMCID: PMC2895332, DOI: 10.1001/jama.2009.476.
• Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs)Kernan WN, Viscoli CM, DeMarco D, Mendes B, Shrauger K, Schindler JL, McVeety JC, Sicklick A, Moalli D, Greco P, Bravata DM, Eisen S, Resor L, Sena K, Story D, Brass LM, Furie KL, Gutmann L, Hinnau E, Gorman M, Lovejoy AM, Inzucchi SE, Young LH, Horwitz RI. Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs). Neurology 2009, 72: 1345-1351. PMID: 19365056, PMCID: PMC2677492, DOI: 10.1212/wnl.0b013e3181a0fda3.
• AMP‐activated protein kinase: a core signalling pathway in the heartKim AS, Miller EJ, Young LH. AMP‐activated protein kinase: a core signalling pathway in the heart. Acta Physiologica 2009, 196: 37-53. PMID: 19239414, DOI: 10.1111/j.1748-1716.2009.01978.x.
• AMP-Activated Protein Kinase Conducts the Ischemic Stress Response OrchestraYoung LH. AMP-Activated Protein Kinase Conducts the Ischemic Stress Response Orchestra. Circulation 2008, 117: 832-840. PMID: 18268160, DOI: 10.1161/circulationaha.107.713115.
• Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heartMiller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008, 451: 578-582. PMID: 18235500, DOI: 10.1038/nature06504.
• Screening for Coronary Artery Disease in Patients With DiabetesBax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. Screening for Coronary Artery Disease in Patients With Diabetes. Diabetes Care 2007, 30: 2729-2736. PMID: 17901530, DOI: 10.2337/dc07-9927.
• Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) StudyWackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study. Diabetes Care 2007, 30: 2892-2898. PMID: 17682123, DOI: 10.2337/dc07-1250.
• Insulin Sensitivity, Vascular Function, and Iron Stores in Voluntary Blood DonorsZheng H, Patel M, Cable R, Young L, Katz SD. Insulin Sensitivity, Vascular Function, and Iron Stores in Voluntary Blood Donors. Diabetes Care 2007, 30: 2685-2689. PMID: 17630263, DOI: 10.2337/dc07-0748.
• Infusion of a biotinylated bis-glucose photolabel: a new method to quantify cell surface GLUT4 in the intact mouse heartMiller EJ, Li J, Sinusas KM, Holman GD, Young LH. Infusion of a biotinylated bis-glucose photolabel: a new method to quantify cell surface GLUT4 in the intact mouse heart. AJP Endocrinology And Metabolism 2007, 292: e1922-e1928. PMID: 17341550, DOI: 10.1152/ajpendo.00170.2006.
• Aging-Associated Reductions in AMP-Activated Protein Kinase Activity and Mitochondrial BiogenesisReznick RM, Zong H, Li J, Morino K, Moore IK, Yu HJ, Liu ZX, Dong J, Mustard KJ, Hawley SA, Befroy D, Pypaert M, Hardie DG, Young LH, Shulman GI. Aging-Associated Reductions in AMP-Activated Protein Kinase Activity and Mitochondrial Biogenesis. Cell Metabolism 2007, 5: 151-156. PMID: 17276357, PMCID: PMC1885964, DOI: 10.1016/j.cmet.2007.01.008.
• Diabetes Mellitus and Cardiovascular DiseaseChyun DA, Young LH. Diabetes Mellitus and Cardiovascular Disease. Nursing Clinics Of North America 2006, 41: 681-695. PMID: 17059982, DOI: 10.1016/j.cnur.2006.07.007.
• AMP-activated protein kinase regulates the assembly of epithelial tight junctionsZhang L, Li J, Young LH, Caplan MJ. AMP-activated protein kinase regulates the assembly of epithelial tight junctions. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 17272-17277. PMID: 17088526, PMCID: PMC1859922, DOI: 10.1073/pnas.0608531103.
• Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imagingPapaioannou GI, Kasapis C, Seip RL, Grey NJ, Katten D, Wackers FJ, Inzucchi SE, Engel S, Taylor A, Young LH, Chyun DA, Davey JA, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Heller GV. Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. Journal Of Nuclear Cardiology 2006, 13: 362-368. PMID: 16750781, DOI: 10.1016/j.nuclcard.2006.01.022.
• Activation of AMPK α- and γ-isoform complexes in the intact ischemic rat heartLi J, Coven DL, Miller EJ, Hu X, Young ME, Carling D, Sinusas AJ, Young LH. Activation of AMPK α- and γ-isoform complexes in the intact ischemic rat heart. AJP Heart And Circulatory Physiology 2006, 291: h1927-h1934. PMID: 16648175, DOI: 10.1152/ajpheart.00251.2006.
• AMP-Activated Protein Kinase Activates p38 Mitogen-Activated Protein Kinase by Increasing Recruitment of p38 MAPK to TAB1 in the Ischemic HeartLi J, Miller EJ, Ninomiya-Tsuji J, Russell RR, Young LH. AMP-Activated Protein Kinase Activates p38 Mitogen-Activated Protein Kinase by Increasing Recruitment of p38 MAPK to TAB1 in the Ischemic Heart. Circulation Research 2005, 97: 872-879. PMID: 16179588, DOI: 10.1161/01.res.0000187458.77026.10.
• Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic SyndromeDrexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. Metabolic Syndrome And Related Disorders 2005, 3: 147-173. PMID: 18370723, DOI: 10.1089/met.2005.3.147.
• AMP-Activated Protein Kinase: A Key Stress Signaling Pathway in the HeartYoung LH, Li J, Baron SJ, Russell RR. AMP-Activated Protein Kinase: A Key Stress Signaling Pathway in the Heart. Trends In Cardiovascular Medicine 2005, 15: 110-118. PMID: 16039971, DOI: 10.1016/j.tcm.2005.04.005.
• AMPK – A pivotal rheostat in the control of cardiac metabolismMiller E, Russell R, Li J, Young L. AMPK – A pivotal rheostat in the control of cardiac metabolism. Drug Discovery Today Disease Mechanisms 2005, 2: 93-100. DOI: 10.1016/j.ddmec.2005.05.008.
• Dual Mechanisms Regulating AMPK Kinase Action in the Ischemic HeartBaron SJ, Li J, Russell RR, Neumann D, Miller EJ, Tuerk R, Wallimann T, Hurley RL, Witters LA, Young LH. Dual Mechanisms Regulating AMPK Kinase Action in the Ischemic Heart. Circulation Research 2005, 96: 337-345. PMID: 15653571, DOI: 10.1161/01.res.0000155723.53868.d2.
• Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic SubjectsWackers F, Young L, Inzucchi S, Chyun D. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects. Diabetes Care 2005, 28: 232-233. DOI: 10.2337/diacare.28.1.232.
• Heart Failure and Cardiac Dysfunction in DiabetesYoung L, Russell R, Chyun D. Heart Failure and Cardiac Dysfunction in Diabetes. 2005, 555-578. DOI: 10.1385/1-59259-908-7:555.
• Screening for coronary artery disease in diabetic patients: The DIAD studyInzucchi S, Young L, Chyun D, Wackers F. Screening for coronary artery disease in diabetic patients: The DIAD study. British Journal Of Diabetes 2004, 4: 317-319. DOI: 10.1177/14746514040040050501.
• AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injuryRussell RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. Journal Of Clinical Investigation 2004, 114: 495-503. PMID: 15314686, PMCID: PMC503766, DOI: 10.1172/jci19297.
• Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics–Brachial Artery Reactivity study)Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics–Brachial Artery Reactivity study). The American Journal Of Cardiology 2004, 94: 294-299. PMID: 15276091, DOI: 10.1016/j.amjcard.2004.04.022.
• Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic SubjectsWackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects. Diabetes Care 2004, 27: 1954-1961. PMID: 15277423, DOI: 10.2337/diacare.27.8.1954.
• Diastolic Function and Type 1 DiabetesYoung LH. Diastolic Function and Type 1 Diabetes. Diabetes Care 2004, 27: 2081-2083. PMID: 15277445, DOI: 10.2337/diacare.27.8.2081.
• Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscleLi J, Hu X, Selvakumar P, Russell RR, Cushman SW, Holman GD, Young LH. Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. AJP Endocrinology And Metabolism 2004, 287: e834-e841. PMID: 15265762, DOI: 10.1152/ajpendo.00234.2004.
• Cardiac myocyte‐specific HIF‐1α deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heartHuang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, Johnson RS, Giordano FJ. Cardiac myocyte‐specific HIF‐1α deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. The FASEB Journal 2004, 18: 1138-1140. PMID: 15132980, DOI: 10.1096/fj.04-1510fje.
• Cardiac Abnormalities in Diabetic Patients With NeuropathyJohnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, Law G, Wackers FJ, Young LH. Cardiac Abnormalities in Diabetic Patients With Neuropathy. Diabetes Care 2004, 27: 448-454. PMID: 14747227, DOI: 10.2337/diacare.27.2.448.
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureNesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure. Diabetes Care 2004, 27: 256-263. PMID: 14693998, DOI: 10.2337/diacare.27.1.256.
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureNesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure. Circulation 2003, 108: 2941-2948. PMID: 14662691, DOI: 10.1161/01.cir.0000103683.99399.7e.
• Insulin resistance and the effects of thiazolidinediones on cardiac metabolismYoung LH. Insulin resistance and the effects of thiazolidinediones on cardiac metabolism. The American Journal Of Medicine 2003, 115: 75-80. PMID: 14678870, DOI: 10.1016/j.amjmed.2003.09.013.
• Physiological role of AMP-activated protein kinase in the heart: graded activation during exerciseCoven DL, Hu X, Cong L, Bergeron R, Shulman GI, Hardie DG, Young LH. Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. AJP Endocrinology And Metabolism 2003, 285: e629-e636. PMID: 12759223, DOI: 10.1152/ajpendo.00171.2003.
• Detection of ischemia in asymptomatic diabetics: Preliminary results of the DIAD studyWackers F, Young L, Inzucchi S, Chyun D, Davey J. Detection of ischemia in asymptomatic diabetics: Preliminary results of the DIAD study. Journal Of The American College Of Cardiology 2003, 41: 409. DOI: 10.1016/s0735-1097(03)81197-x.
• Diagnosis of CAD in patients with diabetes: Who to evaluateYoung LH, Jose P, Chyun D. Diagnosis of CAD in patients with diabetes: Who to evaluate. Current Diabetes Reports 2003, 3: 19-27. PMID: 12643142, DOI: 10.1007/s11892-003-0048-3.
• AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivationZong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2002, 99: 15983-15987. PMID: 12444247, PMCID: PMC138551, DOI: 10.1073/pnas.252625599.
• Cardiac outcomes after myocardial infarction in elderly patients with diabetes mellitus.Chyun D, Vaccarino V, Murillo J, Young LH, Krumholz HM. Cardiac outcomes after myocardial infarction in elderly patients with diabetes mellitus. American Journal Of Critical Care 2002, 11: 504-19. PMID: 12425401, DOI: 10.4037/ajcc2002.11.6.504.
• Acute myocardial infarction in the elderly with diabetesChyun D, Vaccarino V, Murillo J, Young LH, Krumholz HM. Acute myocardial infarction in the elderly with diabetes. Heart & Lung 2002, 31: 327-339. PMID: 12487011, DOI: 10.1067/mhl.2002.126049.
• Correlation of myocardial p-(123)I-iodophenylpentadecanoic acid retention with (18)F-FDG accumulation during experimental low-flow ischemia.Shi CQ, Young LH, Daher E, DiBella EV, Liu YH, Heller EN, Zoghbi S, Wackers FJ, Soufer R, Sinusas AJ. Correlation of myocardial p-(123)I-iodophenylpentadecanoic acid retention with (18)F-FDG accumulation during experimental low-flow ischemia. Journal Of Nuclear Medicine 2002, 43: 421-31. PMID: 11884504.
• Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesisBergeron R, Ren J, Cadman K, Moore I, Perret P, Pypaert M, Young L, Semenkovich C, Shulman G. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. AJP Endocrinology And Metabolism 2001, 281: e1340-e1346. PMID: 11701451, DOI: 10.1152/ajpendo.2001.281.6.e1340.
• Cardiac responses to insulin-induced hypoglycemia in nondiabetic and intensively treated type 1 diabetic patientsRussell R, Chyun D, Song S, Sherwin R, Tamborlane W, Lee F, Pfeifer M, Rife F, Wackers F, Young L. Cardiac responses to insulin-induced hypoglycemia in nondiabetic and intensively treated type 1 diabetic patients. AJP Endocrinology And Metabolism 2001, 281: e1029-e1036. PMID: 11595660, DOI: 10.1152/ajpendo.2001.281.5.e1029.
• Activation of glucose transport in the ischemic heart: Translocation of GLUT4 and GLUT1 by 5′-AMP-activated protein kinaseYoung L, Russell R, Coven D, Shulman G, Sinusas A. Activation of glucose transport in the ischemic heart: Translocation of GLUT4 and GLUT1 by 5′-AMP-activated protein kinase. Journal Of Molecular And Cellular Cardiology 2001, 33: a145. DOI: 10.1016/s0022-2828(01)90556-5.
• Effect of 5-Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside Infusion on In Vivo Glucose and Lipid Metabolism in Lean and Obese Zucker RatsBergeron R, Previs S, Cline G, Perret P, Russell III R, Young L, Shulman G. Effect of 5-Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside Infusion on In Vivo Glucose and Lipid Metabolism in Lean and Obese Zucker Rats. Diabetes 2001, 50: 1076-1082. PMID: 11334411, DOI: 10.2337/diabetes.50.5.1076.
• Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery diseaseMcNulty P, Jacob R, Deckelbaum L, Young L. Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery disease. Metabolism 2000, 49: 1365-1369. PMID: 11079831, DOI: 10.1053/meta.2000.9510.
• Liver Disease in Patients with Hereditary Hemorrhagic TelangiectasiaGarcia-Tsao G, Korzenik J, Young L, Henderson K, Jain D, Byrd B, Pollak J, White R. Liver Disease in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal Of Medicine 2000, 343: 931-936. PMID: 11006369, DOI: 10.1056/nejm200009283431305.
• Cellular and molecular regulation of cardiac glucose transportYoung L, Coven D, Russell R. Cellular and molecular regulation of cardiac glucose transport. Journal Of Nuclear Cardiology 2000, 7: 267-276. PMID: 10888399, DOI: 10.1016/s1071-3581(00)70016-x.
• Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICARRussell R, Bergeron R, Shulman G, Young L. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. American Journal Of Physiology 1999, 277: h643-h649. PMID: 10444490, DOI: 10.1152/ajpheart.1999.277.2.h643.
• Regulation of myocardial glucose uptake and transport during ischemia and energetic stressYoung L, Russell R, Yin R, Caplan M, Ren J, Bergeron R, Shulman G, Sinusas A. Regulation of myocardial glucose uptake and transport during ischemia and energetic stress. The American Journal Of Cardiology 1999, 83: 25-30. PMID: 10750583, DOI: 10.1016/s0002-9149(99)00253-2.
• Effect of AMPK activation on muscle glucose metabolism in conscious ratsBergeron R, Russell R, Young L, Ren J, Marcucci M, Lee A, Shulman G. Effect of AMPK activation on muscle glucose metabolism in conscious rats. American Journal Of Physiology 1999, 276: e938-e944. PMID: 10329989, DOI: 10.1152/ajpendo.1999.276.5.e938.
• Insulin-like growth factor I stimulates cardiac myosin heavy chain and actin synthesis in the awake ratYoung L, Renfu Y, Hu X, Chong S, Hasan S, Jacob R, Sherwin R. Insulin-like growth factor I stimulates cardiac myosin heavy chain and actin synthesis in the awake rat. American Journal Of Physiology 1999, 276: e143-e150. PMID: 9886960, DOI: 10.1152/ajpendo.1999.276.1.e143.
• Additive Effects of Hyperinsulinemia and Ischemia on Myocardial GLUT1 and GLUT4 Translocation In VivoRussell R, Yin R, Caplan M, Hu X, Ren J, Shulman G, Sinusas A, Young L. Additive Effects of Hyperinsulinemia and Ischemia on Myocardial GLUT1 and GLUT4 Translocation In Vivo. Circulation 1998, 98: 2180-2186. PMID: 9815873, DOI: 10.1161/01.cir.98.20.2180.
• Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo.Young L, Renfu Y, Russell R, Hu X, Caplan M, Ren J, Shulman G, Sinusas A. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 1997, 95: 415-22. PMID: 9008459, DOI: 10.1161/01.cir.95.2.415.
• Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia.McNulty PH, Sinusas AJ, Shi CQ, Dione D, Young LH, Cline GC, Shulman GI. Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia. Journal Of Clinical Investigation 1996, 98: 62-69. PMID: 8690805, PMCID: PMC507401, DOI: 10.1172/jci118778.
• IGF-I stimulation of muscle protein synthesis in the awake rat: permissive role of insulin and amino acidsJacob R, Hu X, Niederstock D, Hasan S, McNulty PH, Sherwin RS, Young LH. IGF-I stimulation of muscle protein synthesis in the awake rat: permissive role of insulin and amino acids. American Journal Of Physiology 1996, 270: e60-e66. PMID: 8772474, DOI: 10.1152/ajpendo.1996.270.1.e60.
• Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance.McNulty P, Louard R, Deckelbaum L, Zaret B, Young L. Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance. Circulation 1995, 92: 2151-6. PMID: 7554195, DOI: 10.1161/01.cir.92.8.2151.
• Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia.Shi CQ, Sinusas AJ, Dione DP, Singer MJ, Young LH, Heller EN, Rinker BD, Wackers FJ, Zaret BL. Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. Journal Of Nuclear Medicine 1995, 36: 1078-86. PMID: 7769431.
• Effect of insulin on rat heart and skeletal muscle phenylalanyl-tRNA labeling and protein synthesis in vivoYoung LH, Stirewalt W, McNulty PH, Revkin JH, Barrett EJ. Effect of insulin on rat heart and skeletal muscle phenylalanyl-tRNA labeling and protein synthesis in vivo. American Journal Of Physiology 1994, 267: e337-e342. PMID: 8074214, DOI: 10.1152/ajpendo.1994.267.2.e337.
• Metabolic imaging: What are the challenges?Young L, McNulty P. Metabolic imaging: What are the challenges? Journal Of Nuclear Cardiology 1994, 1: 213-217. PMID: 9420689, DOI: 10.1007/bf02984094.
• Response of rat heart and skeletal muscle protein in vivo to insulin and amino acid infusionMcNulty PH, Young LH, Barrett EJ. Response of rat heart and skeletal muscle protein in vivo to insulin and amino acid infusion. American Journal Of Physiology 1993, 264: e958-e965. PMID: 8333520, DOI: 10.1152/ajpendo.1993.264.6.e958.
• Protein synthesis in pulmonary arteries from rats exposed to hyperoxiaStirewalt WS, Coflesky JT, Young LH, Evans JN. Protein synthesis in pulmonary arteries from rats exposed to hyperoxia. American Journal Of Physiology 1993, 264: l74-l79. PMID: 8430819, DOI: 10.1152/ajplung.1993.264.1.l74.
• Physiological hyperinsulinemia inhibits myocardial protein degradation in vivo in the canine heart.Young LH, Dahl DM, Rauner D, Barrett EJ. Physiological hyperinsulinemia inhibits myocardial protein degradation in vivo in the canine heart. Circulation Research 1992, 71: 393-400. PMID: 1628395, DOI: 10.1161/01.res.71.2.393.
• Physiologic hyperinsulinemia inhibits canine myocardial protein degradation in vivoYoung L, Dahl D, Rauner D, Barrett E. Physiologic hyperinsulinemia inhibits canine myocardial protein degradation in vivo. Journal Of Molecular And Cellular Cardiology 1992, 24: s26. DOI: 10.1016/0022-2828(92)92934-5.
• Myocardial protein turnover in patients with coronary artery disease. Effect of branched chain amino acid infusion.Young LH, McNulty PH, Morgan C, Deckelbaum LI, Zaret BL, Barrett EJ. Myocardial protein turnover in patients with coronary artery disease. Effect of branched chain amino acid infusion. Journal Of Clinical Investigation 1991, 87: 554-560. PMID: 1991838, PMCID: PMC296343, DOI: 10.1172/jci115030.
• In vivo measurement of myocardial protein turnover using an indicator dilution technique.Revkin JH, Young LH, Stirewalt WS, Dahl DM, Gelfand RA, Zaret BL, Barrett EJ. In vivo measurement of myocardial protein turnover using an indicator dilution technique. Circulation Research 1990, 67: 902-912. PMID: 2208613, DOI: 10.1161/01.res.67.4.902.
• Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplastyYoung L, Jaffe C, Revkin J, McNulty P, Cleman M. Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. The American Journal Of Cardiology 1990, 65: 986-990. PMID: 2327360, DOI: 10.1016/0002-9149(90)91001-m.
• Physiologic hyperinsulinemia stimulates lactate extraction by heart muscle in the conscious dogYoung L, Zaret B, Barrett E. Physiologic hyperinsulinemia stimulates lactate extraction by heart muscle in the conscious dog. Metabolism 1989, 38: 1115-1119. PMID: 2682138, DOI: 10.1016/0026-0495(89)90049-8.
• Effect of Chronic Diabetes on Myocardial Fuel Metabolism and Insulin SensitivityBarrett E, Schwartz R, Young L, Jacob R, Zaret B. Effect of Chronic Diabetes on Myocardial Fuel Metabolism and Insulin Sensitivity. Diabetes 1988, 37: 943-948. PMID: 3290011, DOI: 10.2337/diab.37.7.943.
• An isotopic method for measurement of muscle protein synthesis and degradation in vivoBarrett EJ, Revkin JH, Young LH, Zaret BL, Jacob R, Gelfand RA. An isotopic method for measurement of muscle protein synthesis and degradation in vivo. Biochemical Journal 1987, 245: 223-228. PMID: 3663148, PMCID: PMC1148103, DOI: 10.1042/bj2450223.
• Myocardial amino acid transport by canine sarcolemma vesiclesYoung LH, Zaret BL, Barrett EJ. Myocardial amino acid transport by canine sarcolemma vesicles. American Journal Of Physiology 1987, 252: h1070-h1076. PMID: 3035946, DOI: 10.1152/ajpheart.1987.252.6.h1070.
• Agonist regulation of the human platelet alpha-adrenergic receptor.Cooper B, Handin RI, Young LH, Alexander RW. Agonist regulation of the human platelet alpha-adrenergic receptor. Nature 1978, 274: 703-6. PMID: 209342, DOI: 10.1038/274703a0.